Compare Adaptive Biotechnologies Corp (ADPT) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Oatly Group AB - ADR — how do they compare? Adaptive Biotechnologies Corp trades at $25.05 (market cap $4.04B), while Oatly Group AB - ADR trades at $13.09 (market cap $415.98M). The key difference: Adaptive Biotechnologies Corp is far larger — about 9.7× Oatly Group AB - ADR's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Oatly Group AB - ADR nearer its low. Which is the better fit depends on your goals.
| ADPT | OTLY | |
|---|---|---|
Market Cap | $4.04B | $415.98M |
Sector | Health | Consumer Staples |
52-Week High | $25.45 | $18.54 |
52-Week Low | $12.30 | $8.03 |
Enterprise Value | $4.10B | $920.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
OTLY trades at $13.12, down 4.37% today, but maintains a bullish technical outlook with strong moving average and oscillator signals. The company reported Q2 2026 revenue growth and raised full-year guidance, showing progress toward profitability with improving gross margins. However, negative net income and cash flow challenges persist, with the stock trading at a low P/S ratio of 0.44 but elevated P/B of 79.9.
The investment case hinges on OTLY's operational turnaround and revenue acceleration, but significant risks remain from cash burn and high debt levels. Analyst sentiment is mixed with 44% buy ratings, while technical indicators suggest near-term support at $13. The path to sustainable profitability remains the key catalyst for stock appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
